Premium
Sci‐Fri PM: Radiation Therapy, Planning, Imaging, and Special Techniques ‐ 03: The Potential Benefit Of Esophageal Sparing During Palliative Radiotherapy For Lung Cancer
Author(s) -
Granton Patrick V.,
Palma David A.,
Louie Alexander V.
Publication year - 2016
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.4961846
Subject(s) - medicine , esophagitis , esophagus , radiation therapy , lung cancer , esophageal cancer , radiology , pneumonitis , radiation treatment planning , nuclear medicine , cancer , complication , lung , disease , reflux
Puropose: Palliative radiotherapy is an effective technique to alleviate systems of disease burden in late‐stage lung cancer patients. Previous randomized controlled studies demonstrated a survival benefit in patients with good performance status at radiation doses of 35Gy10 or greater but with an increased incidence of esophagitis. The objective of this planning study was to assess the potential impact of esophageal‐sparing IMRT (ES‐IMRT) compared to the current standard of care using parallel‐opposed pair beams (POP). Methods: In this study, 15 patients with lung cancer treated to a dose of 30Gy in 10 fractions between August 2015 and January 2016 were identified. Radiation treatment plans were optimized using ES‐IMRT by limiting the max esophagus point dose to 24Gy. Using published Lyman‐Kutcher‐Burman normal tissue complication probabilities (LKB‐NTCP) models, both plans were evaluated for the likelihood of esophagitis (≥ grade 2) and pneumonitis (≥ grade 2). Results: Using ES‐IMRT, the median esophageal and lung mean doses reduced from 16 and 8Gy to 7 and 7Gy, respectively. Using the LKB models, the theoretical probability of symptomatic esophagitis and pneumonitis reduced from 13 to 1%, and from 5 to 3%, respectively. The median NTD mean for the GTV and PTV of the clinically approved POP plans compared to the ES‐IMRT plans were similar. Conclusions: Advanced radiotherapy techniques such as ES‐IMRT may have clinical utility in reducing treatment‐related toxicity in advanced lung cancer patients. Our data suggests that the rate of esophagitis can be reduced without compromising tumour control.